CN1081682A - 甾类衍生物 - Google Patents

甾类衍生物 Download PDF

Info

Publication number
CN1081682A
CN1081682A CN93105203A CN93105203A CN1081682A CN 1081682 A CN1081682 A CN 1081682A CN 93105203 A CN93105203 A CN 93105203A CN 93105203 A CN93105203 A CN 93105203A CN 1081682 A CN1081682 A CN 1081682A
Authority
CN
China
Prior art keywords
halogen
hydrogen
substituted
unsubstituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93105203A
Other languages
English (en)
Chinese (zh)
Inventor
R·A·阿彻
L·S·比弗斯
R·A·加斯基
H·-S·林
D·B·麦克卢尔
J·R·麦考文
J·M·波拉克
A·A·兰帕索德
R·J·施米特
T·A·施赖耶
M·J·余
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1081682A publication Critical patent/CN1081682A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0029—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0011—Unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN93105203A 1992-03-27 1993-03-26 甾类衍生物 Pending CN1081682A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85890892A 1992-03-27 1992-03-27
US858,908 1992-03-27
US1898593A 1993-03-03 1993-03-03
US018,985 1993-03-03

Publications (1)

Publication Number Publication Date
CN1081682A true CN1081682A (zh) 1994-02-09

Family

ID=26691704

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93105203A Pending CN1081682A (zh) 1992-03-27 1993-03-26 甾类衍生物

Country Status (12)

Country Link
EP (1) EP0562849A2 (enExample)
JP (1) JPH0656670A (enExample)
CN (1) CN1081682A (enExample)
AU (1) AU3551493A (enExample)
BR (1) BR9301342A (enExample)
CA (1) CA2092766A1 (enExample)
CZ (1) CZ50593A3 (enExample)
FI (1) FI931373A7 (enExample)
HU (1) HUT64082A (enExample)
IL (1) IL105050A0 (enExample)
MX (1) MX9301653A (enExample)
NO (1) NO931117L (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1063449C (zh) * 1996-12-27 2001-03-21 中国科学院广州化学研究所 一种胆甾醇化合物及其提取方法
CN111973606A (zh) * 2019-05-22 2020-11-24 王伟 一种化合物治疗血管增生以及糖尿病视网膜病变的新用途
WO2023143398A1 (zh) * 2022-01-28 2023-08-03 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724174B1 (fr) 1994-09-06 1997-01-17 Roussel Uclaf Procede de preparation d'un derive steroide 17beta-carboxy et nouveaux intermediaires
US6444659B1 (en) * 1996-11-28 2002-09-03 Cognis Deutschland Gmbh Use of mixtures of active substances, containing phytostenols and/or phytostenol esters and potentiators, for the production of hypocholesterolemic agents
US6531462B2 (en) 1997-11-06 2003-03-11 Riken Medicament for treating obesity and improving lipid metabolism
JP3873097B2 (ja) * 1997-11-06 2007-01-24 独立行政法人理化学研究所 抗肥満剤及び脂質代謝改善剤
US6093389A (en) * 1997-12-01 2000-07-25 American Cyanamid Company Methods and compositions for attracting and controlling termites
GB9804861D0 (en) 1998-03-06 1998-04-29 Res Inst Medicine Chem Chemical compounds
US6579862B1 (en) 1999-01-12 2003-06-17 Council Of Scientific & Industrial Research Method of treating hyperlipidemic and hyperglycemic conditions in mammals using pregnadienols and pregnadienones
JP4309661B2 (ja) * 2001-05-03 2009-08-05 ザ ユニバーシティー オブ シカゴ 肝臓ｘ受容体
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US20070197484A1 (en) * 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
AU2002356919B2 (en) * 2001-11-08 2008-04-17 The University Of Chicago Method of treating disorder related to high cholesterol concentration
WO2003039480A2 (en) * 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
JP2013500986A (ja) 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓ｘ受容体アゴニスト
EP2822556A1 (en) * 2012-03-07 2015-01-14 Ligand Pharmaceuticals Inc. Steroid hormone and cholesterol pathways as one unified homestatic system
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
WO2023205801A2 (en) 2022-04-22 2023-10-26 Asteroid Therapeutics Steroidal compositions and methods of treating lipogenic cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH372297A (de) * 1959-02-10 1963-10-15 Ciba Geigy Verfahren zur Herstellung von 4-2-tert.-Aminomethyl-3-keto-steroiden
US3256302A (en) * 1960-10-20 1966-06-14 Parke Davis & Co 2-hydroxymethylene-17alpha-ethinyl-17beta-hydroxy-19-nor-4-androsten-3-one
US3314977A (en) * 1962-06-18 1967-04-18 Searle & Co Optionally 17alpha-alkylated 3-oxygenated 2alpha-dialkylaminomethyl-5alpha-androstan-17beta-ols and esters thereof
GB1015214A (en) * 1963-03-11 1965-12-31 Merck Ag E Cholesterol derivatives and preparation thereof
US3980638A (en) * 1974-09-20 1976-09-14 The Upjohn Company Testosterone derivatives
CH643566A5 (de) * 1977-08-29 1984-06-15 Searle & Co 25-alkylcholesterin-derivate.
US4297350A (en) * 1978-10-10 1981-10-27 The Upjohn Company Male contraceptive steroids and methods of use
JP2550777B2 (ja) * 1990-06-29 1996-11-06 日立化成工業株式会社 ステロイドケトン系化合物，その製造法，非線形光学材料および非線形光学素子

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1063449C (zh) * 1996-12-27 2001-03-21 中国科学院广州化学研究所 一种胆甾醇化合物及其提取方法
CN111973606A (zh) * 2019-05-22 2020-11-24 王伟 一种化合物治疗血管增生以及糖尿病视网膜病变的新用途
CN111973606B (zh) * 2019-05-22 2023-05-12 王伟 一种化合物治疗血管增生以及糖尿病视网膜病变的新用途
WO2023143398A1 (zh) * 2022-01-28 2023-08-03 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用

Also Published As

Publication number Publication date
NO931117D0 (no) 1993-03-25
EP0562849A3 (enExample) 1994-02-16
CZ50593A3 (en) 1993-12-15
FI931373L (fi) 1993-09-28
HUT64082A (en) 1993-11-29
HU9300901D0 (en) 1993-06-28
MX9301653A (es) 1994-02-28
AU3551493A (en) 1993-09-30
JPH0656670A (ja) 1994-03-01
NO931117L (no) 1993-09-28
FI931373A7 (fi) 1993-09-28
CA2092766A1 (en) 1993-09-28
BR9301342A (pt) 1993-10-05
IL105050A0 (en) 1993-07-08
FI931373A0 (fi) 1993-03-26
EP0562849A2 (en) 1993-09-29

Similar Documents

Publication Publication Date Title
CN1268626C (zh) 用作mGluR2拮抗剂I的二氢－苯并[b][1,4]二氮杂䓬－2－酮衍生物
CN1041054C (zh) 含有甾类5－α－还原酶抑制剂的药物组合物制备方法
CN1021445C (zh) 制备在位置17含有螺环的新的甾族化合物的方法
CN1230163C (zh) 与雌激素联合的2－苯基－1－[4－(2－氨基乙氧基)－苄基]－吲哚
CN1031942C (zh) 新的药用甾体的制备方法
CN1061052C (zh) 11β－芳基－4－雌烯及其药物上适宜的酸加成盐的制药应用
CN1290700A (zh) 苯基哌嗪衍生物
CN1930181A (zh) 螺旋12定向的甾族药品
CN1680425A (zh) 作为抗炎剂的17β－硫代羧酸酯17α－芳基羰氧基雄甾烷衍生物
CN1832928A (zh) 以5元杂环为基础的p38激酶抑制剂
CN1286693A (zh) 11β－卤素－7α－经取代的雌三烯、制备包含所述11β－卤素－7α－经取代的雌三烯的药物制剂的方法以及该物质在制备药物中的应用
CN1106003A (zh) 微粒体甘油三酯转移蛋白的抑制剂和方法
CN1085223A (zh) 17-β-取代的-4-氮杂-5α-雄烷-3-酮衍生物
CN1599606A (zh) 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法
CN1105362A (zh) 降低血清胆固醇的方法
CN1035055C (zh) 不饱和的17β-取代的3-羧基甾族化合物的制备方法
CN1080639A (zh) 5-α-睾酮还原酶的抑制剂
CN1084846A (zh) 乙醇胺衍生物
CZ50593A3 (en) Steroid derivative, process of its preparation and a pharmaceutical preparation in which said derivative is comprised
CN1138458A (zh) 前列腺癌的治疗和预防
CN101076538A (zh) 用于癌症治疗的类固醇
HK1052511B (zh) 雌激素激动剂/拮抗剂代谢物
CN1046166A (zh) 含有11β-羟酸链的新的19-去甲甾体化合物的制备方法
CN1469743A (zh) 雌激素受体调节剂
CN1348461A (zh) 具有激动或拮抗激素性质的17β－酰基－17α－丙炔基－11β－芳基甾族化合物及其衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication